कंपनी का अवलोकन
AN2 Therapeutics, Inc. operates as a biopharmaceutical entity dedicated to the discovery and development of novel small molecule therapeutics, with its primary clinical focus on epetraborole, a candidate currently undergoing phase 3 trials for the treatment of non-tuberculous mycobacterial lung disease. The company functions within the healthcare sector, specifically inside the biotechnology industry, a segment characterized by high research and development expenditures and reliance on successful clinical trial outcomes to generate future revenue streams. As of the latest data, the organization employs a workforce of 21 individuals, reflecting a lean operational structure typical of early-stage biotech firms. The current market capitalization stands at $109.62M, while annual revenue and sales figures are not available for calculation due to data limitations; this valuation metric suggests the company is a micro-cap entity where equity value is driven primarily by asset potential and clinical pipeline progress rather than established earnings or sales volume. The absence of reported revenue in the financial data indicates that the company is likely in a pre-commercialization phase, where the market cap represents investor confidence in the future commercialization of its pipeline assets rather than current operational profitability.
वित्तीय स्वास्थ्य
The financial statements for AN2 Therapeutics, Inc. report a net income of $-35,174,000 for the trailing twelve months, while revenue and EBITDA figures are listed as N/A, indicating that the company has not yet achieved commercial sales necessary to calculate these standard profitability metrics. The significant negative net income relative to zero revenue highlights a cost structure dominated by research, development, and clinical trial expenses that exceed any current income generation. Free cash flow is recorded at $-18,382,124, which signifies that the company is burning cash to fund its operations and clinical programs, thereby limiting its immediate financial flexibility to expand without external capital injection. All three margin metrics—gross margin, operating margin, and profit margin—are reported as 0.0%, a standard presentation for pre-revenue biotechnology companies where no cost of goods sold or operating profit has been generated from sales. The company holds cash reserves of $58.00M against a total debt load of $0, creating a conservative balance sheet that provides a substantial runway for funding operations without the burden of interest payments. Although the debt-to-equity ratio is listed as N/A due to the lack of equity data in the provided metrics, the zero debt position confirms the firm is not leveraged and faces no solvency risk from borrowing costs. The current ratio stands at 6.87, indicating a robust short-term liquidity position where current assets significantly exceed current liabilities, ensuring the company can meet its obligations even during periods of high cash burn. Return on Equity is -52.1% and Return on Assets is -30.9%, metrics that reflect the dilution of shareholder value and the consumption of assets to fund development efforts rather than generating returns in the current period.
मूल्यांकन आकलन
The trailing P/E ratio is listed as N/A due to the company's lack of earnings, while the forward P/E is reported as -3.81, a metric that is technically invalid for a loss-making entity but suggests the market is pricing in future earnings expectations that are highly speculative. The price-to-book ratio is 1.58, indicating that the market values the company at 1.58 times its book value, which often reflects the intangible value of the clinical pipeline and intellectual property rather than tangible assets. The price-to-sales ratio and EV/EBITDA are both N/A, as these traditional valuation multiples cannot be calculated without positive sales or earnings data, forcing reliance on alternative metrics like market cap and cash reserves for assessment. The stock has traded between a 52-week low of $1.00 and a 52-week high of $6.91, with the current price position relative to this range dependent on real-time market data not provided in the static facts, though the wide band demonstrates significant price volatility over the past year. The beta coefficient is -1.32, a negative value that is highly unusual for equities and suggests an inverse correlation to the broader market or data reporting anomalies, implying extreme sensitivity to market movements that deviates from standard beta behavior.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, preventing a direct comparison of earnings growth versus revenue growth as neither metric exists in the current financial period. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning that all available cash and retained earnings are reinvested into research and development activities rather than distributed to shareholders. This reinvestment strategy is standard for biotechnology firms in the development phase, where capital is prioritized for advancing clinical candidates like epetraborole rather than providing income to investors. The overall growth and income profile is characterized by high cash burn and zero current income, relying entirely on the potential future commercial success of the drug pipeline to transition from a loss-making entity to a profitable revenue generator.